BIOPURE CASE STUDY PDF

Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy. See our Privacy Policy and User Agreement for details.

Author:Zulkihn Mooguzahn
Country:Madagascar
Language:English (Spanish)
Genre:History
Published (Last):10 December 2016
Pages:479
PDF File Size:18.16 Mb
ePub File Size:12.10 Mb
ISBN:869-7-13293-912-5
Downloads:57922
Price:Free* [*Free Regsitration Required]
Uploader:Tetaxe



With this set price of immediate launch, Biopure will reach breakeven point for Oxyglobin in year with the amount of 2. Targeting market for Oxyglobin is emergency care practices as a higher price of blood substitute is more acceptable amongst pet owners. Direct sales method to emergency care practices in big city area is preferable to maximize profit while emergency care practices in medium-to-small city area will be approached by distributors to increase sales.

SWOT analysis has been used with product offering attributes in order to suggest the appropriate strategy relating to the targeting market, which is introduced in the last section. The recommended market strategy is analyzed in accordance with the market objectives, financial objectives, and the 4Ps marketing mix. In order to evaluate and make a decision, we analyze the blood substitute markets along with the analysis of the two scenarios.

Higher demands than supplies — Because the demands of bloods are over the supplies, there are still many rooms of opportunities. For example, the company can charge higher price along with launching many more products to fill the gap of needs. It can be very challenging to the new comers to compete with the big other existing firms, not only due to their larger resource, but also from reputation and professional trust.

The FDA approval for the blood substitutes — The process of approval for medical is very complicated and time consuming. The company must provide the supporting data to FDA to prove their product condition and quality to ensure that their products can use as the blood for medical treatment and this process may take in years. Specific regulations on medical products vary locally and the process also may take long. Although Oxyglobin has been placed on a number of clinical trial for FDA approval, its long term side effect has never been investigated.

These two products need to prove themselves of their effectiveness in blood transfusion market. Moreover, allergy to blood substitute have to be considered. If the products are sold nationwide and severe allergic cases are discovered, this will drastically affect sales of Oxyglobin and Hemopure.

Besides, the bovine source can be skeptical for compatibility of usage in human and other animals. Is there any effect of using bovine red blood cells in human? Uncertainty of market acceptance of blood substitute as they confront deeply rooted blood transfusion treatment, which is proved to be very effective.

Pricing strategy is also essential to the success of products. Normally in animal blood transfusion market, the price a customer buys blood substitute from veterinary practice is double the price that the manufacturer sells to that veterinary practice.

So if prices are set too high, a lot of customers will not be interested in trying blood substitute. They will still use blood transfusion. Without strong establishment of effective result of using blood substitute instead of blood transfusion, the firm cannot go for premium prices in these markets.

Furthermore, how well the firm is able to segment the market, target and tackle it, e. Which distribution channel the firm will use also play a significant role in determining the firm success in introducing new products to market. Being the first mover in animal blood substitute imply that the firm has to take a risk on uninformed customer behavior. These products have to penetrate into blood market where a strong competitor, blood donation and transfusion system, still exist.

So the firm needs to develop a strategy as well as alliance to emerge its products to the market. The firm has to persuade hospitals and practices to use blood substitute instead of blood transfusion which will be the hardest step since customers may resist to a huge change. Even though blood substitute provide more benefits than blood transfusion, its effects still be skeptical and unconvincing.

Scenarios Analysis: Advantages vs. Currently, the demand for animal blood substitute is large while the supply of animal blood is relatively small; therefore, there are plenty of opportunities for the company to explore. The company can enjoy a period of being a monopoly in the market. Since Biopure will be the first to penetrate the animal blood substitute market, Biopure owns the first mover-advantage.

In addition to that, Oxyglobin is an innovative product in which Biopure has the power to position Oxyglobin as a premium product, therefore, can charge at a higher price. If the company wish the launch both products simultaneously, the uncertainty of FDA approval for Hemopure may cause delays and prevent the company to capture the current opportunities in the animal blood substitute market. There are several competitors in the human blood substitute market in which they are all in the process of FDA approval.

Blood substitute produced from human blood. From the sets of pros and cons above, we can see that there are more advantages from immediately launching Oxyglobin. Though the company will earn higher profit margin from selling Hemopure in the human blood substitute market, however, there are other uncertainties from Hemopure that affect the timing of product launch, thus, preventing the company to generate revenue.

In conclusion, since the FDA approval for human blood substitute is still uncertain, Biopure should immediately launch Oxyglobin. Biopure will be the first one to break through the animal blood substitution market given that Biopure currently is the only company who attains the FDA approval for animal blood substitute. We see that it is crucial for Biopure to seize this opportunity immediately by launching Oxyglobin.

Biopure can enjoy low level of competition and gain first mover advantages. Biopure can gain a good reputation from Oxyglobin, which can then create a positive impact on Hemopure when launched in the future. From the analysis, if Oxyglobin is launched first, the price of Oxyglobin will affect Hemopure proportionally.

In case Oxyglobin succeed in animal blood market, Biopure can use some aspects of the success model to apply in the human market.

Without having a real and wide use in animal, labs product cannot be proved of its effectiveness. If Oxyglobin works well on animal, not only the firm actually builds its product reputation and trust amongst new users but also establish a solid evidence of effectiveness. Besides, Biopure will set up a convincing justification of price differentiation between Oxyglobin and Hemopure for clinics, hospitals and insurance firms.

On the other hands, if Oxyglobin does not work well in animal or drawback is founded, Biopure will have a chance to improve Oxyglobin and delay a launch of Hemopure. Hemopure is very similar to Oxyglobin, therefore, a drawback of Oxyglobin will directly affect the price of Hemopure and it will definitely increase possibility of product failure. Market plan for Oxyglobin : Market analysis 3. Thus, We considered that the animal blood substitute market should categorized into two segments, i.

However, the clinic that located in big city, especially in the area of rich people lived i. Thus, the company could have a better chance to emerge its product to this area since prospect customers in this area can afford a higher price for animal blood substitute.

Because the blood substitute is the standard product that have to be concurrent with FDA conditions and cannot be differentiated, so the company can sell this item to every customer at the same quality with the same price. However, emergencies care practice mainly accepted only critical cases, which required a huge amount of blood.

Thus, offering more benefits than traditional blood transfusion would be more preferable alternative for pet owners.

Longer shelf life is also an advantage for veterinary practices since donor animals are rare and blood unit expires in short period. This will make practices keep blood substitute for longer period of time. Then we should target each sub-segment with different distribution channels in order to maximize profit.

This approach would help firm to save 30 percent of distribution cost charged by distributors. The company should posit itself as a provider of the best animal blood substitute quality and product differentiation. Firstly, the substitute blood is free of infectious agents and contamination. Secondly, substitute blood has a longer shelf-life, which is two years.

To ensure that our product would be succeed, the company should create brand awareness of our product by launched Oxyglobin at the time that FDA approved. The company has to rely on distributors also. Hence, parts of revenue will be shared. Very blue ocean. Veterinary blood supply is in lack since it requires blood donation. Hence, the demand in animal blood transfusion is still high. They can replicate to make similar or even better product development.

The limitation is from FDA approval process. Since this is the very first product of this technology, long term consequence when applied to various animals may still be unclear. This can be one of the attack point Biopure may receive from rivalries and protagonists. This blood substitution protein is extracted from bovine source and chemically modified to eliminate the infectious agents, purified, and stabilized to be applicable to other animals.

Major attributes of the Oxyglobin include two-year durability, no potential contamination, flexibility in applying to all blood type, and consistency of usage. Market plan for Oxyglobin: Market strategies 4. As we are the only player in the animal blood substitute industry, or Blue Ocean, we can set the price as high as we desire because of no competition in price. By introducing this, Biopure will reach breakeven point at year with net profit of positive 2. Although, net profit from Alternative 2 will be negative in year and , this is only because the discounted price of Oxyglobin is introduced to attract more potential customers.

When — Biopure should launch Oxyglobin into the market as soon as it is ready, given that the product has already been approved by the FDA. Moreover, as of right now, there will be no potential competitors for the next years, since there is no one engaging in animal blood substitute practices. The opportunity cost of not entering the market as a monopoly with Oxyglobin outweighed the risk of jeopardizing pricing opportunity when launching with Hemopure. As a result Biopure should launch itself into the market with Oxyglobin, not only because the market is small and still attractive, but also can generate revenue and possibly profit for further investment.

Moreover, though it is true that Hemopure is in the last process of FDA, anything could happen and the company should not make any projection or plan based on uncertain prospects. Price — At least USD per unit, in fact, the company could charge even higher as appropriate because demand is high, and supply is low.

The Oxyglobin blood substitute is a newly innovated product, which just had been approved by the FDA. Assuming that Biopure launches Oxyglobin right away, where there is no competitor existing in the market yet, the company will automatically become a monopoly. Our recommendation is at least dollars per unit, because the company cannot effort any lower price, in order to recoup the investment cost eg.

R;amp;D, marketing, production, etc. At the same time, cannot risk mispricing by charging too high either, given that there is a close substitute like donor blood available in the market, charging at 80 to dollars per unit for noncritical, and to dollars for critical cases. Though, donor blood is a close substitute for Oxyglobin, the products themselves is different. Biopure can choose to do market survey about the pricing if excess budget is available, or can do trial ;amp; adjusting however is not recommended because delivering consistency is also important.

Place — Biopure should focus on distribution channels where there is high demand. The company can identify potential geographical regions with high demand, by following the population of veterinary clinics. Assuming that clouded areas, there will be higher traffic of the patients, thus will also be higher demand for our product as well.

HERNANDEZ SANDOICA TENDENCIAS HISTORIOGRAFICAS ACTUALES PDF

Biopure Corp.

Executive Summary 2. Situation Analysis a. Human Blood Demand b. Human Blood Pricing c.

JUDITH HALBERSTAM SKIN SHOWS PDF

Biopure Case Study

We use cookies to give you the best experience possible. Oxyglobin and Hemopure are two blood substitutes that Biopure Corporation was developing. Oxyglobin was recently approved by the FDA for veterinary use while Hemapure is estimated to be approved in two years for human use. If Oxyglobin is launched it will be the first blood substitute for the veterinary market a small and price sensitive market.

DISCIPLINE AND PUNISH PANOPTICISM PDF

Biopure Case Study Essay

To browse Academia. Skip to main content. By using our site, you agree to our collection of information through the use of cookies. To learn more, view our Privacy Policy.

AD009 03 PDF

Biopure Case

It is early and Biopure Corp. A virtually identical product for the human market, Hemopure, is in the final stages of testing by Biopure and is expected to gain approval within one to two years. In response to the timing of approval for these two products, there has been a long-running debate within Biopure as how to proceed with Oxyglobin. At odds are those in charge of Oxyglobin, who want to see the animal product released immediately, and those in charge of the Hemopure, who worry that an immediate release of Oxyglobin would create an unrealistically low price expectation for what they feel should be a very high-margin human product. Exacerbating the problem is the nature of the biopharmaceutical industry, where product approval is never a certainty until achieved.

Related Articles